Why Did OrganiGram Holdings (TSXV:OGI) Rise 9.6% Yesterday?

Should you bet on OrganiGram Holdings Inc. (TSXV:OGI)(NASDAQ:OGI) after its upward spiral on September 4, 2019?

| More on:
Hand arranging wood block stacking as step stair with arrow up.

Image source: Getty Images

Shares of Canada-based cannabis company OrganiGram Holdings (TSXV:OGI)(NASDAQ:OGI) rose close to 10% yesterday. The stock closed trading at $6.30 per share. OGI was listed as a public company on August 22, 2019, and closed trading on $6.51 that day. It reached a high of $6.85 on August 28 and a low of $5.5 on September 3.

OGI shares were trading higher after Oppenheimer analyst Rupesh Parikh started coverage on the stock with a “perform” rating, according to one Market Watch report. The report states that a “perform” rating from the investment bank indicates Parikh expects OGI to perform in line with the S&P 500 index.

Parikh remains optimistic about OGI’s positive EBITDA, which is not very common among high-growth cannabis stocks. The fiscal third quarter of 2019 (ending in May) was the fourth quarter in a row where OGI reported a positive EBITDA.

Revenue estimated to rise 485% in 2019

Analysts expect OGI’s sales to rise by 485.2% year over year to $72.74 million in 2019, up from $12.43 million in 2018. Sales are estimated to reach $155.09 million in 2020, a year-over-year growth of 113.2%. OGI is valued at $941.71 million, which is 13 times its 2019 sales. This valuation is in line with other cannabis companies.

While analysts expect OGI earnings per share (EPS) to fall 38.5% in 2019, its EPS is estimated to rise 162.5% in 2020. Comparatively, the stock is trading at a forward P/E ratio of 28.7, indicating that OGI is undervalued and has solid upside potential.

Analysts have a 12-month average target price of $8.82 for OGI. This indicates OGI stock is trading at a discount of 46.3% to the average estimate.

What will drive OGI sales higher?

OGI is a licensed cannabis producer with a presence in all 10 Canadian provinces. OGI is, in fact, one of four licensed producers in Canada with a distribution agreement in all 10 provinces.

The company aims to grow global footprint via international partnerships with a focus on product improvement and innovation. The company has targeted to produce 113,000 kg of cannabis in 2019. According to the company presentation, OGI has invested heavily in biosynthesis to produce cannabinoids at a fraction of the traditional cultivation cost.

Similar to most marijuana manufacturers, OGI is looking to expand into Europe, which is the largest market for medical cannabis products.

OGI reported sales of $24.8 million in the third quarter of 2019. It sold 3,926 kg of dried flower and over 5,000 litres of cannabis oil. Almost 88% of sales were for adult recreational use, while medical sales accounted for 12% of revenue.

Focus on edibles and derivative products

OGI and other cannabis peers will hugely benefit from the licences to sell edible products. These licences are expected to be granted by the end of 2019. OGI has allocated $48 million in capital expenditure to begin the construction of a facility to manufacture edibles and derivative products.

OGI will look to explore two of the largest segments in the edible and derivative market. The vaporizer pens and edibles account for 23% and 13%, respectively, of the recreational market in the United States.

It will be interesting to see if OGI will be able to beat leading cannabis players in terms of market returns going forward.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

A close up image of Canadian $20 Dollar bills
Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »

Marijuana plant and cannabis oil bottles isolated
Energy Stocks

3 Canadian Value Stocks to Buy Right Now

Undervalued Canadian stocks such as Secure Energy should be part of your shopping list in May 2024.

Read more »